öλÔÓéÀֵǼÈë¿ÚÏÂÔØ

µ¼Ê¦ÐÕÃû£ºÆÖ½§
ÐÔ±ð£ºÄÐ
ÈËÆøÖ¸Êý£º312

ËùÊôԺУ£ºÓÒ½­Ãñ×åҽѧԺ
ËùÊôԺϵ£º
Ö°³Æ£º½ÌÊÚ
µ¼Ê¦ÀàÐÍ£º
ÕÐÉúöλÔÓéÀֵǼÈë¿ÚÏÂÔØ£º
Ñо¿ÁìÓò£º 1.ÆÕͨÍâ¿Æ»ù´¡ÓëÁÙ´²2.ÆÕͨÍâ¿ÆÖ×Áö»ù´¡ÓëÁÙ´²
Ñо¿ÁìÓò£º 1.ÆÕͨÍâ¿Æ»ù´¡ÓëÁÙ´²2.ÆÕͨÍâ¿ÆÖ×Áö»ù´¡ÓëÁÙ´² [ÊÕÆð]




ͨѶ·½Ê½ :
µç×ÓÓʼþ£ºpujianym@163.com


¸öÈ˼òÊö :
¹¤×÷¾­Àú£º1988Äê7ÔÂÖÁ½ñ£¬ÓÒ½­Ãñ×åҽѧԺÁÙ´²Ñ§ÔºÍâ¿Æ ÆäÖУº1993Äê3ÔÂÖÁ1994Äê4Ô£¬±±¾©´óѧ½øÐÞѧϰ 2005Äê3ÔÂÖÁ2005Äê6Ô£¬ÖÐɽ´óѧ½øÐÞѧϰ 2002Äê8ÔÂÖÁ2006Äê8Ô£¬¹ãÎ÷Ò½¿Æ´óѧ˶ʿÑо¿Éú°à 2012Äê1ÔÂÖÁ2013Äê1Ô£¬Å¦Ô¼´óѧÎ÷ÄÎɽҽѧÖÐÐÄ£¬²©Ê¿Éú 2001Äê6ÔÂÖÁ½ñ£¬Èθε¨Íâ¿ÆÖ÷ÈÎ 2008Äê6ÔÂÖÁ½ñ£¬¼æÈδóÍâ¿ÆÖ÷ÈÎ
Éç»áÖ÷Òª¼æÖ°£º¹ãÎ÷ÖÐÎ÷Ò½½áºÏÆÕͨÍâ¿ÆѧÊõίԱ»á¸±Ö÷ÈÎίԱ£¬¹ãÎ÷¿¹°©Ð­»á¸Î°©Ñ§ÊõίԱ»á¸±Ö÷ÈÎίԱ£¬¹ãÎ÷ҽѧ»áÆÕͨÍâ¿ÆѧÊõ»á³£Î¯£¬¹ãÎ÷ҽѧ»áÖ×ÁöѧÊõ»á³£Î¯£¬¹ãÎ÷ÖÐÎ÷Ò½½áºÏÍâ¿Æѧ»á³£ÎñίԱ£¬¹ãÎ÷΢´´Íâ¿ÆѧÊõ»áίԱ£¬¹ãÎ÷ÎÀÉú±ê×¼»¯¼¼ÊõίԱ»áίԱµÈ¡£

¿ÆÑй¤×÷ :
Ö÷Òª¿ÆÑÐÏîÄ¿£º(2009Äê1ÔÂ1ÈÕ-ÖÁ½ñºÍ2008Äê»ñÁ¢Ï2009Ä꿪չ¿ÎÌâµÄ¿ÆÑÐÏîÄ¿)
1¡¢¾Þ´óÔ­·¢ÐԸΰ©ÁªºÏ¸ÎÔàÀë¶ÏºÍÞ²Âö½áÔúµÄ¶þ²½¸ÎÇгý¼¼Êõ¹æ·¶Ñо¿¡£¹ãÎ÷Ò½ÁÆÎÀÉúÊÊÒ˼¼Êõ¿ª·¢ÓëÍƹãÓ¦ÓÃÏîÄ¿£¬S201653£¬2017/01-2019/12£¬6ÍòÔª£¬ÔÚÑУ¬Ö÷³Ö 2¡¢¹ÑºË¸ÊËá΢ÕóÁзÖÎö´óÊóÈÈȱѪËðÉ˼°ÔÙ¹à×¢ËðÉ˺ó»ùÒò±í´ïÆ׵ĸı䣨¹ãÎ÷¿Æ¼¼Ìü¹¥¹Ø¿ÎÌ⣬2009Ä꣩£¬Ö÷³Ö 3¡¢ÔÚÃÀ¹ú¹úÁ¢Å¦Ô¼´óѧÎ÷èÍɽҽѧÖÐÐÄHiotis Laboratory ½øÐÐÑо¿¹¤×÷£¬²ÎÓëSpiros P. Hiotis MD µÄ¶àÏî¿ÆÑÐÑо¿£¬Include: ¡øHepatocellular carcinoma in non-cirrhotic hepatitis B patient a prospective analysis of a fibrosis-independent pathway to cancer based on hepatitis B viral DNA levels. ¡øTreatment of advanced metastatic hepatocellular carcinoma with autologous dendritic cell vaccination. ¡øCell based immunotherapy of a model for hepatocellular carcinoma.¡øRisk factors for peritoneal disease and recurrence in gastric cancer.¡øFactors associated with improved survival in patients with gall bladder cancer. 4¡¢CPBL½ÌÓýģʽÔÚÍâ¿Æѧ¼ûÏ°½ÌѧÖеÄʵ¼ùÓëÑо¿¡££¨¹ãÎ÷½ÌÓýÌü×ÊÖú£¬2014Äê¹ãÎ÷¸ßµÈ½ÌÓý½Ìѧ¸Ä¸ï¹¤³ÌÏîÄ¿£©ÔÚÑУ¬Ö÷³Ö¡£ 5¡¢¹ãÎ÷½ÌÓýÌü×ÊÖú£¬YCSZ**£¬Ä¿±êÐÔѪ¹Ü×è¶Ï¶ÔÈËHepG2ϸ°ûÖê¾Þ´ó¸Î°©Ð¡Êó°©Ï¸°ûÉúÎïѧÌØÕ÷Ó°ÏìµÄʵÑéÑо¿£¬2015/03-2017/03£¬3.5Íò£¬ÔÚÑУ¬µ¼Ê¦ 6¡¢ÓÒ½­Ãñ×åҽѧԺ¿ÎÌ⣬ÓÒÒ½¿Æ×Ö2014ÃæÉÏ£¬ÈËHepG2ϸ°ûÖê¾Þ´ó¸Î°©Ä¿±êÐÔѪ¹Ü×è¶ÏСÊóÄ£Ð͵Ľ¨Á¢ÊµÑ飬2015/01-2016/12£¬1Íò£¬ÔÚÑУ¬Ö÷Òª²ÎÓë 7¡¢°ÙÉ«ÊпÆѧÑо¿Óë¼¼Êõ¿ª·¢¿ÎÌ⣬°Ù¿Æ¼Æ×Ö**£¬¿ªÕ¹Öð¶þÆڸγ¬¼«ÏÞÈÝÁ¿ÇгýÊõÖÎÁƾ޴óÔ­·¢ÐԸΰ©µÄÊÖÊõ¼¼ÊõÑо¿£¬2014/12-2016/12£¬ 1Íò£¬ÔÚÑУ¬Ö÷Òª²ÎÓë 8¡¢°ÙÉ«ÊпÆѧÑо¿Óë¼¼Êõ¿ª·¢¿ÎÌ⣬°Ù¿Æ¼Æ×Ö**£¬¸Î¹¦Äܲ»È«¸Î°©ÐÐTACEÊõºó¶þÆÚÇгýµÄÁÙ´²Ñо¿£¬2014/12-2016/12£¬1Íò£¬ÔÚÑУ¬Ö÷Òª²ÎÓë 9¡¢¹ãÎ÷½ÌÓýÌüÏîÄ¿,2011GXLX0463£¬MRCPÔÚ¼±ÐÔµ¨ÄÒÑ׸¹Ç»¾µµ¨ÄÒÇгýÊõÖеÄÓ¦ÓÃÑо¿£¬2011/12-2013/12£¬1Íò£¬ÒѽáÌ⣬Ö÷Òª²ÎÓë 10¡¢¹ãÎ÷ÎÀÉúÌü×Ô³ï¿ÎÌ⣬Z**£¬128ÅÅÂÝÐýCT¶Ôµ¨µÀÒýÁ÷ÊõºóT¹Üñ¼µÀµÄ¹Û²ìÑо¿£¬2012/01-2014/12£¬ÓÒ½­Ãñ×åҽѧԺÁÙ´²Ñ§Ôº×ÊÖú1.2Íò£¬ÒѽáÌ⣬Ö÷Òª²ÎÓë
»ñµÃµÄÖ÷Òª¿ÆÑн±Ï(2010Äê1ÔÂ1ÈÕ-ÖÁ½ñ)£º
¡°Ô­·¢ÐԸΰ©Survivin¼°HGFµÄÏà¹ØÐÔÑо¿¹ØϵÑо¿¡±£¬¹ãÎ÷×ÔÈ»»ù½ð¿ÎÌ⣬½áÌâ¡£
¸öÈËÈÙÓþ£º(2010Äê1ÔÂ1ÈÕ-ÖÁ½ñ) ?£¨1£©ÆÖ½§£¨1/8£©£¬¸¹¾µÏ¸Î×óÍâÒ¶¸Î°©ÇгýÊõ£¬ÖлªÒ½Ñ§»áÍâ¿Æ·Ö»á£¬ ¡°°ÙÈË°Ù²¿¡±ÊÖÊõ¼ÏàÕ¹²¥£¨¸ÎÔྫÑ¡£©ÓÅÐã½±£¬2015 £¨2£©²¢»ñ°ÙÉ«ÊÐÓÅÐãÈ˲Ä£¬¹ãÎ÷ÔÙ½ÌÓýÏȽø¹¤×÷Õߣ¬ÓÒ½­Ãñ×åҽѧԺ ¡°ÓÅÐãÀÏʦ¡±£¬ÓÒ½­Ãñ×åҽѧԺÁÙ´²Ñ§Ôº¡°Ê®¼Ñҽʦ¡±¡¢¡°ÓÅÐã½ÌÓý¹¤×÷Õß¡±µÈ³ÆºÅ¡£
Ñо¿ÉúÅàÑø£ºÒѱÏÒµ3Ãû£»Ä¿Ç°ÓÐÔÚ¶Á˶ʿÑо¿Éú4Ãû£¬ÆäÖÐÍ⼮˶ʿÑо¿Éú1Ãû¡£
½ü5Äê´ú±íÐÔÂÛÎļ°³É¹û£º [1]ÆÖ½§(*)µÈ¡£Association between the ERCC2 Asp312Asn polymorphism and risk of cancer.Oncotarget,2017 Apr 20.doi:10:18632/Oncotarget 17290.(IF:5.008) [2]¸ßÁ¼¿ü£¬ÆÖ½§(*)µÈ¡£×ó²à³¼Î»¸¹Ö±¼¡ÅÔÊӿ׸¹Ç»¾µÏ·ǽâÆÊÐÔ¸ÎÓÒºóÒ¶Çгý15Àý±¨¸æ¡£Öлª¸Îµ¨Íâ¿ÆÔÓÖ¾£¬2017£¬23£¨6£©:421-422 [3]ÀîÎÄ´¨£¬ÆÖ½§(*)µÈ¡£×ó¿¨Äáͨ͡¹ý¼¤»îNrf2/HO-1;¾¶¼õÇá´óÊó¸ÎÔàÈÈȱѪÔÙ¹à×¢ËðÉË [J]¡£Öлª¸Îµ¨Íâ¿ÆÔÓÖ¾£¬2017£»23(2):121-125 [4]Ðí×ôÃ÷£¬ÆÖ½§(*)¡£CTLsÏà¹ØµÄÃâÒßÁÆ·¨Ôڸΰ©ÖÎÁÆÖеÄÐÂÇ°¾°£¬ÊÀ½ç»ªÈËÏû»¯ÔÓÖ¾£¬2017 25(15): DOI: 10.11569/wcjd.v25.i15.0000 [5]ÀîÎÄ´¨£¬ÆÖ½§(*)µÈ¡£ÈÈȱѪÔÙ¹à×¢ËðÉËÔçÆÚ´óÊó¸ÎÔà»ùÒò±í´ïÆ×µÄʵÑéÑо¿¡£ÓÒ½­Ò½Ñ§£¬2017£¬45£¨1£©£º2-6. [6]ÀîÎÄ´¨(#)£¬¸ßÁ¼¿ü£¬ÀîºÆº½£¬Î¤ÇïÒµ£¬Ñî½à£¬Íô½¨³õ£¬ÆÖ½§(*)¡£×ó¿¨ÄáÍ¡¶Ô´óÊó¸ÎÔàÈÈȱѪ¼°ÔÙ¹à×¢ËðÉ˵ı£»¤×÷ÓÃ.ÓÒ½­Ò½Ñ§£¬2016£¬05ÆÚ£¬pp498-501 [7]ÀîÓñ·å,ÆÖ½§(*)µÈ¡£Ð¡¶ùÏÈÌìÐԾ޽᳦¸¹Ç»¾µ¸¨ÖúϸÄÁ¼SoaveÊÖÊõµÄÁÙ´²ÖÎÁÆЧ¹û¡£½áÖ±³¦¸ØÃÅÍâ¿Æ£¬2016Äê,22£¨S1£©£º95-96 [8]¸ßÁ¼¿ü(#)£¬ÆÖ½§(*)¡£¸ÎÔàÀë¶ÏÁªºÏÞ²Âö½áÔú¶þ²½¸ÎÇгýÊõÖÎÁƸÎÔàÖ×Áö¸Å¿ö¡£ÓÒ½­Ò½Ñ§£¬2016£¬44(3) [9]ÀîÎÄ´¨,ÆÖ½§*.¸Îϸ°ûÈÈȱѪ¼°ÔÙ¹à×¢ËðÉ˵ÄÑо¿ÏÖ×´¡£¹ãÎ÷ҽѧ,201638(2):233-235 [10]ÂíÑà·É(#)£¬ÆÖ½§(*)£¬Â¬¹ÚÃú£¬³ÂÓÀ³Ï£¬ñûÇ¿£¬»Æ½£.nm23»ùÒòÔÚÔ­·¢ÐÔÈéÏÙ°©×éÖ¯Öеıí´ï¼°ÒâÒå.ҽѧÁÙ´²Ñо¿£¬2015£¬25£¨8):1582-1583 [11]Íô½¨³õ£¬ÆÖ½§*£¬Ëαó£¬Â½ÌΣ¬ÂíÈÕº££¬ÎâÏͽ¨£¬×¿³¼Ò壬·Զ£¬Íõ´æ´¨¡£ MRI¼°MRCPÔÚ¼±ÐÔµ¨ÄÒÑ׸¹Ç»¾µµ¨ÄÒÇгýÊõÇ°ÆÀ¹ÀÖеÄÓ¦ÓÃ[J]¡£ÖлªÆÕͨÍâ¿ÆÔÓÖ¾£¬2015,30(3):198-200 [12]Íô½¨³õ£¬ÆÖ½§*£¬Íõ´æ´¨£¬ÂíÈÕº££¬Â·Ô¶£¬×¿³¼Ò壬½ÓñÃô¡£µ¨×ܹÜ̽²éÒýÁ÷ÊõºóT¹Üñ¼µÀÐγɵÄÏà¹ØÒòËØ·ÖÎö[J]¡£ÖлªÏû»¯Íâ¿ÆÔÓÖ¾£¬2015£¬14£¨2£©£º141-144 [13]Íô½¨³õ£¬ÆÖ½§*£¬Íõ´æ´¨£¬Â·Ô¶£¬×¿³¼Ò壬ÎâÏͽ¨£¬ÂíÈÕº££¬Â½ÓñÃô¡£¾­ñ¼µÀÔìÓ°ÅжÏÂÝÐýCT¹Û²ìµ¨µÀÒýÁ÷ÊõºóT¹Üñ¼µÀµÄ¿ÉÐÐÐÔÑо¿[J]¡£ÓÒ½­Ãñ×åҽѧԺѧ±¨£¬2015£¬37(2):185-187 [14]ÂíÑà·É£¬ÆÖ½§*¡£ÈýÒõÐÔÈéÏÙ°©·Ö×Ó°ÐÏòÖÎÁƵÄÑо¿½øÕ¹[J]¡£ÖÐÍâÒ½ÁÆ£¬2015£¬£¨11£©£º192-193 [15]»Æ¸¦´ï£¬ÆÖ½§*¡£½ðÁú½ºÄÒÓë¸Î¶¯Âö»¯ÁÆ˨ÈûÊõÁªºÏÖÎÁƽáÖ±³¦°©¸ÎתÒƵÄËæ»ú¶ÔÕÕ·ÖÎö[J]¡£ÏÖ´úÏû»¯¼°½éÈëÕïÁÆ£¬2015£¬20£¨3£©£º287-289 [16]»Æ¸¦´ï£¬Ñî²ýı£¬¹ù¿¡ÓÆÖ½§*¡£¸¹Ç»¾µÖ±³¦°©¸ùÖÎÊõÓëDixon Ö±³¦°©¸ùÖÎÊõÁÙ´²ÁÆЧ¶Ô±È [J]£¬ÊÀ½ç»ªÈËÏû»¯ÔÓÖ¾£¬2014£¬22£¨2£©£º291-295 [17]Íô½¨³õ£¬ÆÖ½§*£¬Î¤°îÄþ£¬ÂíÈÕº££¬Â½ÌΣ¬ÎâÏͽ¨¡£¼±ÐÔµ¨ÄÒÑ׸¹Ç»¾µµ¨ÄÒÇгýÊõµÄÏÖ×´ÓëÖ÷ÒªÎÊÌâ[J]£¬¸¹Ç»¾µÍâ¿ÆÔÓÖ¾£¬2012£¬17£¨1£©£º78-80 [18]Íô½¨³õ£¬ÆÖ½§*£¬Â½ÌΣ¬Î¤°îÄþ£¬ÂíÈÕº££¬ÎâÏͽ¨¡£µ¨µÀT¹ÜÒýÁ÷Êõºóñ¼µÀÐγɵĹ۲ìÑо¿ [J]£¬¸Îµ¨Íâ¿ÆÔÓÖ¾, 2012£¬20£¨5£©£º383-385 »áÒéÌØÑûѧÊõ±¨¸æ£º £¨1£©ÆÖ½§.¸¹Ç»¾µÏÂÓÒ°ë¸ÎÇгýÊÖÊõ¼¼ÇÉ¡£¹ãÎ÷ҽѧ»áÖÐÎ÷Ò½½áºÏÆÕͨÍâ¿Æ·Ö»á2017ÄêѧÊõ»á£¬ÄÏÄþ£¬2017Äê11ÔÂ16-18ÈÕ £¨2£©ÆÖ½§.WLPPSÁÙ´²Ó¦ÓÃÉÌÌÖ¡£¹ãÎ÷ҽѧ»áÆÕͨÍâ¿Æ·Ö»á2017ÄêѧÊõ»á£¬±±º££¬2017Äê10ÔÂ14-16ÈÕ £¨3£©ÆÖ½§.¸¹¾µÏ¸Î×óÍâÒ¶¸Î°©ÇгýÊõ£¬¡°°ÙÈË°Ù²¿¡±ÊÖÊõ¼ÏàÕ¹²¥£¨¸ÎÔྫÑ¡£©£¬2015ÖйúÍâ¿ÆÖÜôßµÚ25½ì¹ú¼ÊÍâ¿Æ¡¢Î¸³¦¿Æ¼°Ö×Áö¿ÆҽʦЭ»á»áÒ飬¸£ÖÝ£¬2015Äê9ÔÂ5-8ÈÕ £¨4£©ÆÖ½§£¬ÒÈÊ®¶þÖ¸³¦ÇгýµÄÈô¸É²ßÂÔ£¬¹ãÎ÷ҽѧ»áÆÕͨÍâ¿Æ·Ö»á2015ÄêѧÊõ»á£¬¹ðÁÖ£¬2015Äê11ÔÂ22-24ÈÕ £¨5£©ÆÖ½§£¬·Ö¶þÆÚµÄÓÒ°ë¸ÎÇгýÊõ£¬¹ãÎ÷ҽѧ»áÆÕͨÍâ¿Æ·Ö»á2013ÄêѧÊõ»á£¬ÄÏÄþ£¬2013Äê11ÔÂ22-24ÈÕ
½üÄê³ö°æÖø×÷Óë½Ì²Ä£º ?£¨1£©ÌÆǬÀû¡¢ÆÖ½§Ö÷±à£¬ÌÆع½ð¡¢»Æº£ÄÜ¡¢³ÂºêÃ÷¸±Ö÷±à£¬Íâ¿Æѧ»ù´¡£¬ÓÒ½­Ãñ×åҽѧԺÁÙ´²Ò½Ñ§±¾¿Æ½Ì¸ÄÕûºÏ½Ì²Ä£¬35Íò×Ö£¬2013.08 £¨2£©ÌÆǬÀû¡¢ÖÜϲººÖ÷±à£¬ÆÖ½§¡¢»ÆÐíÉ­¡¢ñûÔÂÇ︱Ö÷±à£¬Ïû»¯ÏµÍ³¼²²¡£¬ÓÒ½­Ãñ×åҽѧԺÁÙ´²Ò½Ñ§±¾¿Æ½Ì¸ÄÕûºÏ½Ì²Ä,30Íò×Ö£¬2013.8 ?£¨3£©ÁÎÆ·çú¡¢ÌÆع½ðÖ÷±à£¬À×Ö¾Ó¢¡¢ÖÜϲºº¡¢Å˺ì·É¡¢ÆÖ½§¡¢Â½ÔƷɸ±Ö÷±à£¬ÁÙ´²»ù±¾¼¼ÄÜ£¬ÓÒ½­Ãñ×åҽѧԺ½Ì¸ÄÕûºÏ½Ì²Ä, 40Íò×Ö£¬2013.08

½ÌÓý±³¾° :
1983Äê7ÔÂÖÁ1988Äê7Ô£¬¹ãÎ÷Ò½¿Æ´óѧ£¬Ò½Ñ§Ñ§Ê¿£»2002Äê7ÔÂÖÁ2006Äê7Ô£¬¹ãÎ÷Ò½¿Æ´óѧ˶ʿÑо¿Éú°à£¬Ò½Ñ§Ë¶Ê¿£»2012Äê1ÔÂÖÁ2013Äê1Ô£¬¹úÁ¢Å¦Ô¼´óѧÎ÷ÄÎɽҽѧÖÐÐÄ£¬Íâ¿ÆÖ×Áöѧ²©Ê¿